Original language | English (US) |
---|---|
Pages (from-to) | 1558-1559 |
Number of pages | 2 |
Journal | Cancer Cell |
Volume | 39 |
Issue number | 12 |
DOIs | |
State | Published - Dec 13 2021 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Cancer Cell, Vol. 39, No. 12, 13.12.2021, p. 1558-1559.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity
AU - Jing, Ying
AU - Liu, Yuan
AU - Li, Qiang
AU - Ye, Youqiong
AU - Diao, Lixia
AU - Huang, Yun
AU - Zhou, Yubin
AU - Green, Michael R.
AU - Mills, Gordon B.
AU - Han, Leng
N1 - Funding Information: This work was supported by the Cancer Prevention & Research Institute of Texas ( RR150085 and RP190570 to L.H.), NIH ( U01 CA217842 to G.B.M), and The Welch Foundation ( BE-1913-20190330 to Y.Z.). M.R.G is a Scholar of the Leukemia and Lymphoma Society. We thank LeeAnn Chastain for editorial assistance. Detailed methods and list of CAR targets are available at https://hanlab.tamhsc.edu/CARTSC/#!/download , and all other associated data are available within the data portal. Funding Information: This work was supported by the Cancer Prevention & Research Institute of Texas (RR150085 and RP190570 to L.H.), NIH (U01 CA217842 to G.B.M), and The Welch Foundation (BE-1913-20190330 to Y.Z.). M.R.G is a Scholar of the Leukemia and Lymphoma Society. We thank LeeAnn Chastain for editorial assistance. Detailed methods and list of CAR targets are available at https://hanlab.tamhsc.edu/CARTSC/#!/download, and all other associated data are available within the data portal. M.R.G. has stock ownership interest in KDAc Therapeutics; receives funding from Kite/Gilead, Allogene, Sanofi, and Abbvie; and has received an honorarium from Tessa Therapeutics. G.B.M notes personal fees for consulting from Abbvie, Amphista, AstraZeneca, Chrysallis Biotechnology, GSK, ELlipses Pharma, ImmunoMET, Ionis, Lilly, Medacorp, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen, Tarveda, Turbine, and Zentalis Pharmaceuticals; stock options from Catena Pharmaceuticals, ImmunoMet, SignalChem, Tarveda, and Turbine; and has licensed technology of homologous recombination deficiency (HRD) assay to Myriad Genetics and digital saptial profiler (DSP ) patents with Nanostring. All other authors declare no competing interests.
PY - 2021/12/13
Y1 - 2021/12/13
UR - http://www.scopus.com/inward/record.url?scp=85120727682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120727682&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2021.09.016
DO - 10.1016/j.ccell.2021.09.016
M3 - Letter
C2 - 34678153
AN - SCOPUS:85120727682
SN - 1535-6108
VL - 39
SP - 1558
EP - 1559
JO - Cancer Cell
JF - Cancer Cell
IS - 12
ER -